Glucoraphanin for Health & Longevity

Evidence Review created on 11/09/2026 using AI4L + evidence-mcp / Opus 5.5

Also known as: Sulforaphane Glucosinolate, SGS, GR, GRA, 4-Methylsulfinylbutyl Glucosinolate, Glucorafanin, TrueBroc

Motivation

Glucoraphanin is a natural sulfur compound found in broccoli and, at much higher levels, in young broccoli sprouts and seeds. On its own it does little; when the plant is chewed or reaches the gut, an enzyme turns it into sulforaphane, a compound that switches on the body’s own antioxidant and detoxification defenses. It is sold as capsules and tablets, often paired with that converting enzyme, and is also eaten as fresh sprouts.

Interest began with cancer-prevention research at a university laboratory in the early 1990s, followed by sprout-drink studies in a heavily polluted farming region of China, specially bred broccoli in Britain, and standardized sprout-extract capsules developed in Japan. The longevity community took notice because the compound targets a protective pathway that weakens with age, and because the main source is an ordinary vegetable.

This review examines the human evidence on blood fats, memory in older adults and the clearing of pollutants, together with the safety record, how much of each dose the body actually converts, and how preparations differ.

Benefits - Risks - Protocol - Conclusion

The items below give a high-level overview of glucoraphanin, its conversion to sulforaphane and the clinical evidence behind it.

Peter Attia’s site returned no content on glucoraphanin or sulforaphane, and Lifespan.io returned only monthly news digests that mention sulforaphane in passing. Huberman Lab’s sulforaphane material is an interview with Rhonda Patrick, left out so that the same expert is not listed twice, and a brief detoxification segment in Huberman’s own episode The Effects of Microplastics on Your Health & How to Reduce Them, which does not cover glucoraphanin in the depth this list requires.

Grokipedia

  • Glucoraphanin

    Summarizes glucoraphanin’s chemistry, its concentration in sprouts versus mature broccoli, conversion by plant myrosinase or gut bacteria, and the preclinical case for its downstream product sulforaphane.

Examine

No Examine article on glucoraphanin exists; the site search returns no results for the term.

ConsumerLab

No dedicated ConsumerLab article or product review on glucoraphanin exists; the term appears only inside broader, members-only articles on other topics.

Systematic Reviews

The reviews below pool human evidence on sulforaphane-based preparations and glucoraphanin-rich vegetables, including the main safety concern.

Mechanism of Action

Glucoraphanin is a stable, largely inactive precursor; its effects come from sulforaphane, which acts more strongly on protective enzymes in liver-derived cells (Abdull Razis 2013).

  • Conversion: Chewing raw sprouts lets myrosinase (a plant enzyme stored apart from glucoraphanin) cut off its sugar, releasing sulforaphane. Gentle heating inactivates the epithiospecifier protein (which diverts the reaction to an inactive nitrile) (Matusheski 2004) and raises yield (Matusheski 2004). Without myrosinase, gut bacteria convert about 1% to over 40% of a dose (Fahey 2012).
  • Nrf2 activation: Sulforaphane modifies Keap1 (the protein that holds Nrf2 inactive), releasing Nrf2 (a master switch for antioxidant and detoxification genes) to raise enzymes such as NQO1 (an enzyme that neutralizes reactive quinones), as shown in human skin (Chien 2025), showing that it reaches the skin.
  • Pharmacology: Glutathione S-transferases (enzymes that tag compounds for excretion) bind sulforaphane to glutathione (the cell’s main antioxidant molecule) (Shapiro 2001), and it leaves in urine as mercapturic acids (end products of this route) (Shapiro 2001). Plasma half-life is about 1.8 hours (Ye 2002), with active kidney secretion (Ye 2002). It acts on reactive cysteine sites of many proteins, not one receptor. Exposure from glucoraphanin is slower and longer than from preformed sulforaphane (Egner 2011).
  • Competing view: Four weeks of sulforaphane did not raise Nrf2 target genes in the lungs of people with COPD (chronic obstructive pulmonary disease) (Wise 2016), and a review describes how sustained Nrf2 activity can help established tumors resist stress and treatment (Glorieux 2024).

Historical Context & Evolution

  • Original role: Glucoraphanin evolved as part of the crucifer “mustard oil bomb”, a defense in which damaged tissue releases pungent compounds against insects and pathogens; humans encountered it only as part of broccoli and related vegetables.
  • Discovery: In 1992 Paul Talalay’s Johns Hopkins group isolated sulforaphane from broccoli as a potent inducer of protective enzymes (Zhang 1992). In 1997 it reported three-day-old sprouts contain 10–100 times more glucoraphanin than mature broccoli (Fahey 1997).
  • Chemoprevention trials: Chemoprevention (using compounds to prevent cancer) drinks made from sprouts were tested in Qidong, China, a region with heavy exposure to aflatoxin (a mold toxin that causes liver cancer) and air pollution. The first trial found no overall drop in aflatoxin-DNA damage (Kensler 2005), only an inverse relation with each person’s sulforaphane output (Kensler 2005); a later trial found faster excretion of benzene and acrolein (an irritant in smoke and polluted air) (Egner 2014).
  • New sources: A Norwich group bred broccoli with about three times more glucoraphanin from a wild relative (Armah 2015); the cultivar is patented and the lead investigator is a named inventor (Armah 2015). Kagome developed sprout-extract capsules standardized to glucoraphanin in Japan.
  • What changed: Wide person-to-person variation in conversion led to products with added myrosinase, which doubled sulforaphane bioavailability in a randomized trial (Mastaloudis 2026), while an autism trial that missed its primary outcome (Zimmerman 2021) and a glucose reduction smaller than prespecified (Dwibedi 2025) narrowed the early chemoprevention-centered enthusiasm without settling the question.

Expected Benefits

Grades reflect the class of evidence; many trials used broccoli sprouts, extracts that release preformed sulforaphane, or whole broccoli rather than purified glucoraphanin, and such evidence is graded as indirect.

High 🟩 🟩 🟩

No benefit reaches High: each clinical or validated-surrogate finding comes from a single trial or one research group, or from sprout powders and sulforaphane-releasing extracts rather than glucoraphanin itself.

Medium 🟩 🟩

Better Memory and Processing Speed in Older Adults

Three placebo-controlled Japanese trials gave 30 mg glucoraphanin daily as a standardized sprout extract (Nouchi 2021; Nouchi 2022; Shimizu 2026). Two Tohoku University trials in healthy older adults found faster processing speed after 12 weeks (Nouchi 2021; Nouchi 2022), the second also with less negative mood (Nouchi 2022). A 42-month Hirosaki pilot in 26 people with memory impairment found better memory scores over time (Shimizu 2026). All three used Kagome-made supplements with Kagome employees as authors (Nouchi 2021; Nouchi 2022; Shimizu 2026), so the evidence comes from one commercial source.

Magnitude: Memory Performance Index change from baseline at 42 months, median +13.4 points on glucoraphanin versus +3.6 on placebo (p, the probability of a difference this large arising by chance, = 0.079, not significant) (Shimizu 2026); the group-by-time effect (whether the two groups’ scores diverged over time) over the whole study was significant (p = 0.012) (Shimizu 2026).

Low 🟩

Lower LDL Cholesterol ⚠️ Conflicted

Evidence is indirect: glucoraphanin came in whole broccoli. Mithen’s group found 400 g weekly of high-glucoraphanin broccoli lowered LDL more than standard broccoli (Armah 2015); Mithen holds cultivar patents (Armah 2015). An earlier analysis found no differential LDL effect (Armah 2013). Net reading: small reduction, significant only when pooled.

Magnitude: LDL fell 7.1% (95% CI, the range likely to contain the true value, 1.8–12.3%) on high-glucoraphanin broccoli versus 1.8% on standard broccoli in the first trial (Armah 2015) and 5.1% (2.1–8.1%) versus 2.5% in the second (Armah 2015); the pooled between-group difference was significant (p = 0.031), with no pooled figure reported (Armah 2015).

Lower Liver Enzymes in Fatty Liver ⚠️ Conflicted

In men with fatty liver, 30 mg glucoraphanin daily lowered the liver enzymes ALT (alanine aminotransferase) and γ-GTP (gamma-glutamyl transpeptidase) within group, not versus placebo, which the abstract omits (Kikuchi 2015); Kagome sponsored it (Kikuchi 2015). A small trial found no change (Ghorbanian 2026). Net reading: no effect beyond placebo.

Magnitude: Mean ALT change −10.7% versus −4.3% on placebo (Kikuchi 2015) and γ-GTP −8.9% versus −1.1% (Kikuchi 2015); between-group differences were not significant (Kikuchi 2015).

Lower Fasting Glucose and Insulin Resistance ⚠️ Conflicted

Evidence is indirect: sprout powder lowered insulin resistance in type 2 diabetes (Bahadoran 2012). A sulforaphane-releasing extract missed its primary glucose target in prediabetes (Dwibedi 2025). Net reading: at most a small glucose effect, possibly limited to responders.

Magnitude: Fasting glucose fell 0.2 mmol/L more than placebo (95% CI 0.01–0.44), short of the prespecified 0.3 mmol/L (Dwibedi 2025).

Reduced Helicobacter pylori Colonization ⚠️ Conflicted

Evidence is indirect: sprouts, not purified glucoraphanin. Eight weeks of sprouts (420 µmol glucoraphanin daily) lowered Helicobacter pylori (a stomach bacterium linked to ulcers, gastric cancer) markers (Yanaka 2009); alfalfa sprouts did not (Yanaka 2009). A sprout-extract trial found no effect (Chang 2015). Net reading: possible reduction, not eradication.

Magnitude: 8 of 25 participants on sprouts fell below the stool-antigen positivity cutoff after 8 weeks (Yanaka 2009), none on the breath test (Yanaka 2009), and 6 of the 8 turned positive again after stopping (Yanaka 2009); the alfalfa group showed no significant change and the paper gives no matching figure for it, not compared between groups (Yanaka 2009).

Lower Cancer Risk with Broccoli-Rich Diets

A meta-analysis of observational studies links higher broccoli intake with lower cancer risk (Baladia 2024). Evidence is indirect: whole broccoli contains many compounds besides glucoraphanin, and observational designs cannot exclude healthier lifestyles among broccoli eaters.

Magnitude: Cohort studies: relative risk (risk in high consumers divided by risk in low consumers) 0.89 (95% CI 0.82–0.96) for highest versus lowest broccoli intake; the source gives no absolute figures (Baladia 2024).

Neuropsychiatric Symptoms ⚠️ Conflicted ⭕️ Not Central to Health & Longevity

This bears on autism and schizophrenia, not on longevity. Evidence is indirect, mostly sulforaphane-releasing preparations. A meta-analysis found small autism gains (Wang 2025), and one in schizophrenia found no overall effect (Kassar 2025); a glucoraphanin-plus-myrosinase trial using Nutramax-supplied tablets missed its primary outcome (Zimmerman 2021). Net reading: small, inconsistent effects.

Magnitude: Total autism symptoms SMD (standardized mean difference, effect size in standard-deviation units) −0.27 (95% CI −0.42 to −0.12) versus placebo (Wang 2025).

Speculative 🟨

Faster Clearance of Airborne Carcinogens

A glucoraphanin-rich sprout drink raised urinary excretion of benzene and acrolein conjugates versus placebo (Egner 2014); lower doses did not (Chen 2019). These excretion markers are unvalidated against cancer outcomes.

Slower Prostate Cancer Progression

A year of glucoraphanin-rich broccoli soup dose-dependently damped cancer-linked gene expression in men under active surveillance (monitoring instead of immediate treatment) (Traka 2019). The basis is a tissue gene signature, not clinical progression.

Skin Protection

Oral glucoraphanin raised the protective enzyme NQO1 in human skin biopsies about threefold (Chien 2025) but did not reduce ultraviolet-induced skin redness (Chien 2025). The basis is a tissue biomarker in 18 volunteers.

Slower Tissue Aging

Long-term glucoraphanin-enriched kale suppressed skin aging in fast-aging mice through Nrf2 (Chawalitpong 2019). The basis is animal data only; no human aging or lifespan outcome exists.

Benefit-Modifying Factors

  • Gut microbiome: Without plant myrosinase, conversion depends on gut bacteria and ranges from about 1% to over 40% of a dose (Fahey 2012); glucose responders had more of a gut-bacterial gene required for conversion (Dwibedi 2025).
  • Genetic polymorphisms: Carriers of GSTT1 (a gene for a glutathione-attaching detoxification enzyme) excreted more benzene conjugate in both arms (Egner 2014); PAPOLG variants (a gene for an enzyme that adds tails to messenger RNA) shaped metabolic responses to high-glucoraphanin broccoli (Armah 2013).
  • Body mass and baseline glucose: Greater body mass reduced conversion in a study funded by Nutramax, maker of the tested supplement (Fahey 2019); glucose responders had mild obesity, low insulin resistance and reduced insulin secretion (Dwibedi 2025).
  • Sex: Memory scores improved more on glucoraphanin in both women and men over the whole study, though not at the 42-month endpoint alone (Shimizu 2026), and sex had negligible effect on conversion (Fahey 2019).
  • Pre-existing conditions: Mild cognitive impairment (memory decline beyond normal aging) showed greater memory gains (Shimizu 2026); acid suppression raised conversion from uncoated tablets (Fahey 2019), though the authors call overall bioavailability very similar (Fahey 2019); enteric antibiotics abolish microbial conversion (Fahey 2012).
  • Age: Cognitive trials enrolled adults up to 90, with effects emerging only after 30 months in the long trial (Shimizu 2026); age had negligible effect on conversion (Fahey 2019).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse outcome has been shown above placebo in trials from more than one independent research group; reported events are mild and inconsistent.

Medium 🟥 🟥

No risk reaches Medium: the one placebo-controlled signal, digestive upset, came from a sulforaphane-releasing extract and was not reproduced with glucoraphanin-rich drinks.

Low 🟥

Digestive Upset and Unpleasant Taste ⚠️ Conflicted

A sulforaphane-releasing extract caused more nausea, loose stools and reflux than placebo (Dwibedi 2025). A 12-week glucoraphanin-rich drink trial in 291 adults found mild events at similar rates (Egner 2014). Net reading: mild and mostly early.

Magnitude: Grade I (mildest grade) events 4.1% versus 2.8% on placebo, mainly taste and mild stomach discomfort (Egner 2014); losses to follow-up, mainly digestive, 9 of 44 versus 6 of 45 on placebo (Dwibedi 2025).

Foodborne Infection from Raw Sprouts

Raw sprouts grown in warm, humid conditions can carry Salmonella, Listeria or Escherichia coli (Dechet 2014); outbreak surveillance covers all seed sprouts, not broccoli specifically (Dechet 2014). This applies to fresh sprouts, not extracts.

Magnitude: 33 outbreaks and 1,330 reported illnesses from seed and bean sprouts in the United States, 1998–2010; no control group (Dechet 2014).

Speculative 🟨

Thyroid Suppression ⚠️ Conflicted

Isothiocyanates (the class including sulforaphane) may compete with iodine uptake, a goitrogenic (thyroid-enlarging) concern with a mechanistic basis only. A 12-week randomized trial in women found no change (Chartoumpekis 2019). Net reading: no human harm.

Support for Established Cancers

A review describes how sustained Nrf2 activation can help existing tumor cells resist oxidative stress and chemotherapy (Glorieux 2024). The basis is mechanistic and preclinical; no human report links glucoraphanin to tumor growth.

Blunted Training Adaptation

Antioxidant pathway activation could, in theory, dampen exercise signaling. The basis is mechanistic only; a two-week glucoraphanin trial found no change in muscle recovery (Cesanelli 2026).

Risk-Modifying Factors

  • Genetic polymorphisms: No variant is known to raise risk; GSTM1 genotype (a gene for a toxin-conjugating enzyme) did not change how daily broccoli altered isothiocyanate absorption (Charron 2018).
  • Baseline iodine and thyroid status: The thyroid concern applies mainly to low iodine intake; with adequate iodine, a systematic review found no adverse thyroid effect of cruciferous intake (Galanty 2024).
  • Sex: No sex difference in adverse events is reported; the only thyroid trial enrolled women and found no effect (Chartoumpekis 2019). Pregnancy safety at supplement doses is unstudied.
  • Pre-existing conditions: Weakened immunity raises the danger of sprout-borne infection, per the US Food and Drug Administration (FDA produce safety page); active cancer raises the theoretical Nrf2 concern; kidney impairment may slow clearance because sulforaphane metabolites are actively secreted by the kidney (Ye 2002).
  • Age: Older adults are more vulnerable to foodborne illness (FDA produce safety page); capsules for 42 months in adults aged 63–90 produced no adverse-event difference (Shimizu 2026).

Key Interactions & Contraindications

Documented interactions:

  • CYP3A4 substrates (midazolam, simvastatin, tacrolimus): No interaction found: broccoli sprout extract did not change CYP3A4 (the liver enzyme that clears about half of drugs) activity overall (Poulton 2013), nor block its induction by rifampicin (Poulton 2013).
  • CYP1A2 substrates (caffeine, theophylline, clozapine, tizanidine): In a meta-analysis, cruciferous-rich diets raised CYP1A2 (a liver enzyme clearing these drugs) activity by 20–40%, which may lower drug levels (Eagles 2020); purified glucoraphanin is untested. Steady cruciferous intake with narrow-margin drugs mitigates this.
  • Proton pump inhibitors (drugs that suppress stomach-acid production: omeprazole, esomeprazole): Possibly raises conversion: in the same participants, uncoated glucoraphanin-plus-myrosinase tablets yielded 25.7% before versus 33.6% after starting omeprazole (Fahey 2019), though the authors call bioavailability very similar overall (Fahey 2019); no harm reported.
  • Oral antibiotics and bowel cleansing (amoxicillin, bowel preparations): These abolish gut-bacterial conversion of glucoraphanin (Fahey 2012), so enzyme-free products lose effect; myrosinase-containing products or fresh sprouts bypass this.
  • Clarithromycin-based triple therapy (two antibiotics plus an acid-suppressing drug) for Helicobacter pylori: No interaction found: added sulforaphane neither changed eradication rates (Chang 2020) nor adverse events (Chang 2020).
  • Mustard seed powder (supplement, exogenous myrosinase): Additive: doubled sulforaphane bioavailability from glucoraphanin (Mastaloudis 2026).
  • Curcumin (supplement, another Nrf2 activator): Combined use raised skin NQO1 3.6-fold from baseline versus 3.1-fold with glucoraphanin alone and 3.3-fold with curcumin alone, not compared between arms (Chien 2025), without new adverse events (Chien 2025).

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Levothyroxine and thyroid conditions: Inferred from isothiocyanate competition with iodine uptake; consequence would be reduced thyroid hormone output in iodine-poor diets. Checking TSH (thyroid-stimulating hormone) after starting mitigates this.
  • Warfarin (a vitamin K antagonist, an anticoagulant that slows blood clotting by blocking vitamin K): Inferred from the vitamin K content of fresh sprouts (not extracts); large, variable sprout intake could shift INR (a clotting-time measure). Keeping sprout intake consistent mitigates this.
  • Glucose-lowering drugs (metformin, insulin, and sulfonylureas, drugs that make the pancreas release insulin, such as glipizide): Inferred from additive glucose lowering; consequence would be mild extra glucose reduction. Glucose monitoring when starting mitigates this.
  • Chemotherapy agents (doxorubicin, cisplatin): Inferred from Nrf2-driven detoxification, which might reduce drug effect on tumor cells. Pausing during chemotherapy, with oncologist input, mitigates this.
  • Other Nrf2-activating supplements (moringa, other broccoli products): Inferred from a shared pathway; consequence would be additive Nrf2 activation and digestive upset. Counting total daily glucoraphanin and isothiocyanates mitigates this.

Populations who should avoid Glucoraphanin:

  • People with weakened immunity, pregnant women, young children and older adults (raw or lightly cooked sprouts only): Higher risk of severe sprout-borne infection (FDA produce safety page); extracts avoid this.
  • Pregnancy and breastfeeding (supplements): Inferred from isothiocyanate competition with iodine uptake when thyroid hormone demand is raised; no human data on fetal or infant exposure at supplement doses.
  • Untreated hypothyroidism or iodine deficiency: Inferred from isothiocyanate competition with iodine uptake; no human data in this group, and the review finding no harm applied to adequate iodine intake (Galanty 2024).
  • Active cancer under treatment: Inferred from Nrf2-mediated tumor-cell protection in preclinical work summarized in a review (Glorieux 2024); no human data.
  • Mustard allergy (products with mustard-seed myrosinase): Inferred from allergic reaction to mustard seed proteins in the added enzyme source; no glucoraphanin-specific data.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Low starting dose taken with food: Protocols typically begin at half the target dose for one to two weeks to reduce digestive upset; in one 12-week trial, all mild events occurred in the first week (Egner 2014).
  • Extracts or safely grown sprouts: Extracts avoid sprout-borne infection; for vulnerable groups, the FDA lists raw or lightly cooked sprouts as a foodborne-illness risk (FDA produce safety page), preventing Salmonella or Escherichia coli illness.
  • Adequate iodine intake: Iodized salt or seafood several times weekly counters the theoretical thyroid effect; a TSH check at 8–12 weeks in those with thyroid disease detects suppression early.
  • Pausing around cancer treatment: Stopping glucoraphanin during chemotherapy or radiation, with oncologist input, avoids the theoretical Nrf2-mediated tumor protection.
  • Steady intake with CYP1A2 drugs: Stable cruciferous intake while taking theophylline, clozapine or tizanidine prevents unexpected drops in drug levels.

Therapeutic Protocol

Each dose below is cited to its source; timing, splitting, cycling and titration steps without a citation reflect common practice.

  • Standardized glucoraphanin capsules (Kagome): 30 mg glucoraphanin (about 69 µmol) once daily, used for 2 months in a Japanese liver trial (Kikuchi 2015) and 42 months in a cognition trial (Shimizu 2026).
  • Glucoraphanin plus myrosinase tablets (Avmacol, Nutramax): About 2.2 µmol sulforaphane-yield per kg body weight daily in the Johns Hopkins–linked autism trial (Zimmerman 2021).
  • High-dose sprout drink (Johns Hopkins, Kensler and Fahey): 600 µmol glucoraphanin plus 40 µmol sulforaphane daily for 12 weeks in the pollution trial (Egner 2014).
  • Fresh sprouts (popularized by Rhonda Patrick): 70 g fresh broccoli sprouts daily, about 420 µmol glucoraphanin (Yanaka 2009); Patrick discusses broccoli sprouts and adding mustard seed to cooked broccoli (Huberman Lab episode).
  • High-glucoraphanin broccoli (Mithen): 400 g weekly of a high-glucoraphanin cultivar, lightly steamed (Armah 2015).
  • Competing approaches: Whole sprouts, enzyme-free extracts, enzyme-added extracts and stabilized sulforaphane differ mainly in conversion; an enzyme-free glucoraphanin-rich sprout drink yielded about 5% versus 70% for a sulforaphane-rich drink (Egner 2011).
  • Time of day: Glucoraphanin conversion is greater during the day than at night (Fahey 2012); morning or midday dosing with a meal is common practice.
  • Half-life: Sulforaphane has a plasma half-life of about 1.8 hours (Ye 2002); exposure from glucoraphanin is slower and more sustained (Egner 2011).
  • Single or split dosing: Most trials used one daily dose; dosing every 8 hours for 7 days was tolerated (Shapiro 2006). Splitting smooths exposure but adds burden.
  • Myrosinase and chewing: Thorough chewing of sprouts increased conversion (Shapiro 2001), as did mustard seed myrosinase (Mastaloudis 2026).
  • Genetic polymorphisms: GSTT1 variants (Egner 2014) and PAPOLG variants (Armah 2013) modify responses, but no genotype-based dose adjustment exists.
  • Sex: No sex-specific dosing; at the same 30 mg dose, memory scores improved more than placebo in both sexes over the whole study (Shimizu 2026).
  • Age: The 30 mg dose was used without dose change in adults aged 63–90 (Shimizu 2026).
  • Baseline biomarkers: Higher body mass lowers conversion (Fahey 2019), favoring enzyme-added products; mildly obese, insulin-sensitive people with reduced insulin secretion responded best on glucose (Dwibedi 2025).
  • Pre-existing conditions: Recent antibiotic use cuts conversion from enzyme-free products (Fahey 2012); acid suppression raised conversion from uncoated enzyme-added tablets (Fahey 2019), though the authors call overall bioavailability very similar (Fahey 2019).

Discontinuation & Cycling

  • Duration: Used as a long-term dietary measure; the longest trial ran 42 months without an adverse-event difference from placebo (Shimizu 2026).
  • Withdrawal effects: None reported; benefits fade after stopping, as Helicobacter pylori markers returned to baseline within two months (Yanaka 2009).
  • Tapering: Not needed; no rebound or withdrawal effects have been described, so glucoraphanin can be stopped at once.
  • Cycling: No evidence supports cycling; sulforaphane bioavailability did not decline across 12 weeks of daily dosing (Egner 2014), suggesting no tolerance.

Sourcing and Quality

  • Glucoraphanin-only extracts: TrueBroc seed extract and Kagome’s heat-treated sprout extract (Kikuchi 2015) lack active myrosinase, so conversion relies on gut bacteria; an enzyme-free glucoraphanin-rich drink yielded about 5% (Egner 2011). Kagome’s 42-month trial capsules added mustard powder (Shimizu 2026).
  • Glucoraphanin plus myrosinase: Avmacol (Nutramax) and Life Extension Optimized Broccoli with Myrosinase add enzyme; mustard seed myrosinase doubled bioavailability (Mastaloudis 2026).
  • What to look for: Labels stating milligrams of glucoraphanin per dose and active myrosinase, plus testing seals from USP (United States Pharmacopeia) or NSF International; enteric coating (dissolving past the stomach) improved conversion (Fahey 2019) but caused far more adverse events (Fahey 2019).
  • Fresh sprouts and seeds: Sprouts hold 10–100 times more glucoraphanin than mature broccoli (Fahey 1997); seeds sold for sprouting, ideally pathogen-tested, lower contamination risk.
  • Labeling pitfalls: Products sold as “sulforaphane” often contain glucoraphanin, and enzyme-free versions yield far less sulforaphane than labels imply; trial-used brands (Avmacol, Kagome) offer the best-characterized option.

Practical Considerations

  • Time to effect: Detoxification markers shifted within 7 days (Kensler 2012); LDL changes appeared at 12 weeks (Armah 2015); memory differences emerged only after 30 months (Shimizu 2026).
  • Common pitfalls: Heating broccoli to 70 °C or above lowers sulforaphane formation (Matusheski 2004); swallowing sprouts unchewed lowers conversion (Shapiro 2001); enzyme-free extracts may convert poorly in people with low-converting gut bacteria.
  • Regulatory status: Sold in the United States as a dietary supplement, which the FDA does not approve before marketing (FDA dietary supplement Q&A); no drug approval exists for any indication.
  • Cost and access: Not exceptionally expensive; home-grown sprouts cost little, and no institutional payer covers glucoraphanin, so no payer incentive shapes its research.

Interaction with Foundational Habits

  • Sleep: None known: no trial reports sleep improvement; rare insomnia appeared in an autism trial (Zimmerman 2021). Morning dosing avoids any evening stimulation.
  • Nutrition: Potentiating: mustard seed (Mastaloudis 2026) or daikon radish (Egner 2011) supplies myrosinase, which vitamin C typically activates (FoundMyFitness sulforaphane topic page); heating broccoli to 60 °C raises yield (Matusheski 2004), while 70 °C or above lowers it in florets (Matusheski 2004). No nutrient depletion is reported.
  • Exercise: None observed: two weeks of high-glucoraphanin broccoli powder did not change strength recovery, soreness or creatine kinase (a muscle-damage marker) after eccentric (muscle-lengthening) exercise (Cesanelli 2026). Blunting of training adaptation remains theoretical.
  • Stress management: Indirect: 12 weeks of glucoraphanin reduced negative mood scores in healthy older adults (Nouchi 2022); no study has measured cortisol or the stress response.

Monitoring Protocol & Defining Success

Baseline testing before starting covers the markers glucoraphanin is expected to change: a fasting lipid panel for LDL cholesterol and fasting glucose, with ALT (a liver enzyme) as a safety check. People with known thyroid disease, iodine-poor diets or a history of cancer add a TSH test and a discussion with their physician, since these are the groups in which theoretical risks apply. A simple cognitive baseline, such as a timed processing-speed test, gives a personal reference point.

Ongoing monitoring repeats the lipid panel, ALT and glucose at 12 weeks, matching the trial durations, and then every 6–12 months. TSH is rechecked at 8–12 weeks only in the higher-risk groups above. Success is defined as a sustained LDL reduction against one’s own baseline, stable liver enzymes, good digestive tolerance, and stable or improving cognitive test scores over years rather than weeks.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
LDL cholesterol <100 mg/dL, “optimal” category of NCEP ATP III Expected to change: may fall modestly Category from NCEP ATP III (National Cholesterol Education Program Adult Treatment Panel III guideline); conventional laboratory reference below 130 mg/dL (varies by lab); fasting 9–12 h preferred; pair with triglycerides and HDL (high-density lipoprotein) cholesterol
ALT (alanine aminotransferase) About 7–55 U/L (standard reference range) Safety check: liver ALT is a liver-injury enzyme; avoid strenuous exercise 48 h before testing; pair with AST (aspartate aminotransferase, another liver enzyme)
Fasting glucose 70–99 mg/dL (standard reference range) Expected to change: may fall slightly Fast 8–12 h; morning draw; pair with fasting insulin for HOMA-IR (homeostatic model assessment of insulin resistance, an insulin-resistance index)
TSH About 0.4–4.0 mIU/L (standard reference range) Safety check: thyroid, only in higher-risk groups Only for known thyroid disease or iodine-poor diets; morning draw; pair with free thyroxine if abnormal; ranges vary by lab

Qualitative markers:

  • Digestive tolerance: absence of nausea, loose stools or reflux after the first week.
  • Cognitive clarity: subjective sharpness and self-administered processing-speed or memory tests.
  • Mood: fewer low or irritable days, the dimension that improved in older adults.
  • Energy levels: daily energy and fatigue, tracked against baseline.

Emerging Research

  • Smokers’ carcinogen detoxification: A phase 2 trial of Avmacol ES in about 135 heavy smokers measures benzene and acrolein detoxification over 12 weeks (NCT05121051). Positive results would extend the detoxification signal to smokers; a null result would weaken it.
  • Firefighters’ detoxification: A 72-participant phase 2 trial of broccoli seed and sprout extract (NCT06009926) passed its primary completion in February 2026; no results posted. Positive results would support occupational use; null would weaken the detoxification case.
  • Cognition in mild cognitive impairment: A 12-week Korean trial in about 100 adults aged 50–85 tests broccoli sprout extract on cognitive scores (NCT07334366). A positive result would provide the first non-Kagome replication; a null result would weaken the cognition benefit.
  • Neurodegenerative disease: An open-label (unblinded) randomized Italian study of myrosinase-activated glucoraphanin versus standard therapy in about 300 participants, adults with Parkinson’s disease or multiple sclerosis and children with neuromuscular or degenerative diseases (NCT07360977), reached primary completion in October 2026; no results posted. Positive results would justify blinded trials; null results would temper neurological claims.
  • Chemotherapy heart protection: A phase 1/2 trial in about 70 breast cancer patients tests sulforaphane against doxorubicin heart damage (NCT03934905). Protection without reduced cancer control would ease the theoretical chemotherapy concern; a null result would leave it unresolved, and harm would reinforce it.
  • Microbiome-guided responders: Identifying converters by gut bacterial genes (Dwibedi 2025) and adding myrosinase (Mastaloudis 2026) could explain inconsistent trials or show most people gain little.
  • Nrf2 and cancer risk: Whether long-term Nrf2 activation protects or aids early cancers remains open, as a review sets out (Glorieux 2024); human surveillance data could strengthen or weaken the safety case.

Conclusion

Glucoraphanin is the inactive plant compound in broccoli, especially in sprouts and seeds, that the body converts into sulforaphane, a switch for its own antioxidant and detoxification defenses. For health-focused adults, its appeal is that it targets a protective system that weakens with age, using a familiar food source.

The human evidence is modest. The strongest finding is better memory and processing speed in older adults taking glucoraphanin capsules; a small drop in harmful cholesterol from specially bred broccoli is less certain. Both rest on one research program each, and the memory work was funded by the capsule’s maker, while the broccoli was bred by scientists who hold patents on it. Faster clearing of air pollutants remains speculative: trials in one region of China showed it only as changes in urine markers. Effects on liver enzymes, blood sugar, stomach bacteria and autism or schizophrenia symptoms are small, inconsistent, or come from related preparations rather than glucoraphanin itself.

How much of each dose the body converts varies enormously between people and depends on gut bacteria and on whether the product contains the plant’s own converting enzyme, which helps explain mixed results. Side effects are mild and mostly digestive. Raw sprouts carry a risk of foodborne infection, the long-feared thyroid effect has not appeared in people with enough iodine, and the possibility of helping existing tumors remains theoretical. Overall, the evidence base is promising but early, narrow and partly commercially funded.

Top - Benefits - Risks - Protocol